Sorrento Therapeutics (SRNE) is a development stage biopharmaceutical company focused on the development and commercialization of proprietary drug therapeutics for cancer and cancer pain. The company is also developing therapeutic products for other indications, including inflammation, metabolic disorders, and infectious diseases.
Sorrento's pipeline consists of lead oncology product candidate Cynviloq™, a polymeric micellar nanoparticle paclitaxel formulation, resiniferatoxin (RTX), a non-opiate, ultra potent and selective agonist of the TRPV-1 receptor for cancer pain, as well as fully human therapeutic antibodies derived from its proprietary G-MAB® library platform and antibody drug conjugates (ADCs).
Cynviloq, Next Generation of Abraxane ®
Cynviloq is Sorrento's lead cancer drug candidate. Cynviloq™ is a next-generation nanoparticle...
Only subscribers can access this article, which is part of the PRO research library covering 3,613 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: